iBio Announces MUC16 as its Latest Immune-Oncology Target Program

Rhea-AI Summary

iBio has announced its latest immune-oncology program targeting MUC16, a protein overexpressed in various solid tumors, including ovarian and pancreatic cancers. Utilizing its patented epitope steering AI platform, iBio's new monoclonal antibodies aim to bind to an unmodifiable region of MUC16, enhancing the effectiveness of cancer treatment by circumventing tumor evasion mechanisms. This addition expands iBio's immuno-oncology portfolio, which already includes programs targeting other cancer-specific proteins. The company emphasizes its commitment to advancing innovative treatments in the biopharmaceutical space.

Positive

• Introduction of a novel immune-oncology program targeting MUC16 demonstrates innovation.
• Use of patented epitope steering AI technology enhances effectiveness against tumors.
• Expansion of immuno-oncology portfolio with complementary programs for diverse cancer types.

Negative

• None.

- Company has directed antibodies against a specific region of MUC16 -

- Potentially offers a differentiated and effective tool in the fight against cancer -

BRYAN, Texas, Feb. 16, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the disclosure of MUC16 as the target of it’s latest immune-oncology program.

MUC16 is a well-known cancer target often overexpressed in several types of solid tumors, including ovarian, lung, and pancreas cancers. Specifically, MUC16 is a large extracellular protein expressed on more than 80% of ovarian tumors. Tumor cells can evade immune attack by shedding or glycosylating MUC16, making it difficult for traditional antibody therapies to effectively target and destroy the cancer cells.

Using its patented epitope steering AI platform, iBio's innovative approach to this challenge allows its new monoclonal antibodies (mAbs) to bind to a specific region of MUC16 that is not shed or glycosylated, circumventing both tumor evasion mechanisms and potentially providing a powerful tool in the fight against cancer.

"The targeting of a very specific, patho-physiologically relevant, region of MUC16 is a testament to the versatility of our AI technology, as it successfully shows it can be applied to a broad range of targets,” said iBio’s Interim Chief Executive Officer and Chief Scientific Officer, Martin Brenner. "This success adds to the growing list of target classes to which we have made differentiated antibodies using our patented epitope steering technology."

With the addition of the MUC16 program, iBio expands its Immuno-Oncology Portfolio complementing its Treg depleting programs IBIO-101 and CCR8, as well as its program targeting the tumor-specific EGFRvIII protein.

About iBio, Inc.

iBio develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. iBio’s mission is to decrease drug failures, shorten drug development timelines, and open up new frontiers against the most promising targets. For more information, visit www.ibioinc.com.

FORWARD-LOOKING STATEMENTS

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the guarantee of broad coverage of the Company’s proprietary, epitope-steering antibody discovery engine and the engine providing iBio a competitive advantage. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to continue to execute its growth strategy; its ability to obtain regulatory approvals for commercialization of its product candidates, or to comply with ongoing regulatory requirements; regulatory limitations relating to its ability to promote or commercialize its product candidates for specific indications; acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products; its ability to maintain its license agreements; the continued maintenance and growth of its patent estate; its ability to obtain or maintain the capital or grants necessary to fund its research and development activities and whether the Company will incur unforeseen expenses or liabilities or other market factors; successful compliance with governmental regulations applicable to its manufacturing facility; competition; its ability to retain its key employees or maintain its NYSE American listing; and the other factors discussed in the Company’s filings with the SEC including the Company’s Annual Report on Form 10-K for the year ended June 30, 2022 and the Company’s subsequent filings with the SEC on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and the Company undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Contact:

Stephen Kilmer
iBio, Inc.
Investor Relations
(646) 274-3580
skilmer@ibioinc.com

FAQ

What is iBio's latest immune-oncology program targeting?

iBio's latest immune-oncology program targets MUC16, a protein overexpressed in numerous solid tumors.

How does iBio's technology improve cancer treatment?

iBio uses its epitope steering AI platform to develop monoclonal antibodies that bind to a specific region of MUC16, potentially enhancing treatment efficacy.

Which cancers are associated with MUC16?

MUC16 is often found in ovarian, lung, and pancreatic cancers.

What other programs does iBio have in its immuno-oncology portfolio?

iBio's portfolio includes Treg depleting programs IBIO-101 and CCR8, alongside its MUC16-targeting program.

On what date was the announcement made regarding iBio's new program?

The announcement was made on February 16, 2023.